Follow us for updates
© 2021
Read the Story →

Regeneron Says COVID Antibody Treatment May Be Less Effective vs Omicron

Challenged by the new variant.
by Agence France Presse
A day ago
Photo/s: shutterstock

WASHINGTON -- U.S. biotech firm Regeneron said Tuesday that its synthetic antibody treatment for COVID-19 may be less effective against the new variant, and it plans to conduct tests to determine by how much.

"Prior in vitro analyses and structural modeling regarding the individual mutations present in the Omicron variant indicate that there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody-conveyed immunity, including the current REGEN-COV antibodies," the company said in a statement.

"Further analyses are ongoing to confirm and quantify this potential impact using the actual Omicron variant sequence."

REGEN-COV is currently authorized in the United States as a post-exposure prophylaxis in high-risk individuals, and is pending full approval.


WHO Backs Regeneron to Treat High-Risk COVID Patients

Regeneron Says COVID Antibody Treatment Protects for at Least 8 Months

It is based on two lab-produced monoclonal antibodies -- Y-shaped proteins that bind to the spikes that dot the surface of the coronavirus, stopping the pathogen from invading human cells.

Continue reading below ↓

The antibodies, called casirivimab and imdevimab, are injected intravenously.

But Omicron has a high number of mutations on its spike proteins, which worries health experts.

The World Health Organization in late September recommended Regeneron for COVID-19 treatment, but only in patients with specific health profiles, such as the elderly or those with weakened immune systems.

Continue reading below ↓
Recommended Videos

Reportr is now on Quento. Download the app or visit the Quento website for more articles and videos from Reportr and your favorite websites.

Latest Headlines
Read Next
Recent News
Minimum public health standards must be observed.
To sustain the vaccination program's momentum.
Figure out which data plan works best for you.
It was only a matter of time.
He has yet to pay damages for killing mother and son.
The news. So what? Subscribe to the newsletter that explains what the news means for you.
The email address you entered is invalid.
Thank you for signing up to On Three, reportr's weekly newsletter delivered to your mailbox three times a week. Only the latest, most useful and most insightful reads.
By signing up to newsletter, you agree to our Terms of Service and Privacy Policy.